v3.25.4
Collaborative and Other Relationships - Lily (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended 193 Months Ended
Oct. 31, 2025
Dec. 31, 2009
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2025
License agreements            
Total revenues     $ 5,141,242 $ 4,241,217 $ 3,695,649  
Eli Lilly            
License agreements            
Upfront payment received under license agreement $ 100,000         $ 100,000
Eli Lilly | OLUMIANT            
License agreements            
Total revenues     $ 144,600 $ 135,600 $ 136,100  
Development Milestones | Eli Lilly            
License agreements            
Amount recognized and received for the achievement of a predefined milestone           149,000
Development Milestones | Maximum | Eli Lilly            
License agreements            
Upfront and immediate milestone payment to be received under license agreement   $ 150,000        
Regulatory Milestones | Eli Lilly            
License agreements            
Amount recognized and received for the achievement of a predefined milestone           335,000
Regulatory Milestones | Maximum | Eli Lilly            
License agreements            
Upfront and immediate milestone payment to be received under license agreement   365,000        
Commercialization Milestones | Eli Lilly            
License agreements            
Amount recognized and received for the achievement of a predefined milestone           $ 50,000
Commercialization Milestones | Maximum | Eli Lilly            
License agreements            
Upfront and immediate milestone payment to be received under license agreement   $ 150,000